Lucy Liu

Lucy Liu is an accomplished professional with extensive experience in the life sciences and biotechnology sectors. Currently serving as a Principal at Longwood Fund since July 2020, Lucy Liu leads due diligence efforts for new company opportunities and syndicated investments. In addition to this role, Lucy Liu holds positions as a Board Observer for AAVantgarde Bio and Carbon Biosciences, where efforts are focused on advancing gene therapy technologies. Previous roles include Head of Strategy at ImmuneID, where Lucy Liu contributed to innovative immunology solutions, and a Fellow at 5AM Ventures, assisting in new company formation and investment diligence. A former Damon Runyon Postdoctoral Fellow at Harvard Medical School, Lucy Liu conducted research on adipokine signaling in the nervous system. Lucy Liu earned a PhD in Neuroscience from Baylor College of Medicine, focusing on lipid metabolic perturbations related to Alzheimer's disease, and holds a Bachelor's degree in Biology and Chemistry from the University of North Carolina at Chapel Hill.